
|Articles|July 1, 2003
Antigen Activation
Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Demonstrates Positive Effects on TCS Use, Growth in Pediatric Patients
2
Arcutis Completes Enrollment in Phase 2 Study of Roflumilast Cream for Infant AD
3
Pilot Study Tests Oral NAC as Adjunct in Vitiligo Therapy
4
Future Therapeutic Pathways and Combination Strategies in Vitiligo Management
5



















